RxDoctor Payments Data

Claudia Craig, PA

Physician Assistant · Indianapolis, INNPI 1225757941

Payments from drug & device makers

$2,504in general payments, 2019–2025

Across 87 payments — averaging $28.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$608
  • Gilead$464
  • Takeda Pharmaceuticals U.S.A., Inc.$352
  • Madrigal Pharmaceuticals$291
  • Sequana Medical US Inc.$222
  • Ardelyx, Inc.$99
  • plus $468 from 10 others

What the payments were for

  • Food & beverage$2,49199%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,504 in reported general payments places this provider in the 85th percentile of 1,955 physician assistant providers in Indiana.

See all physician assistant providers in Indiana

Medicare billing

Part B allowed, 2024
$22,573
Medicare patients
175
Services billed
230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin14$47,377
LinzessLinaclotide22$19,556
Mesalamine DrMesalamine12$3,211
Colestipol Hcl45$2,779
Esomeprazole Magnesium84$1,943
Omeprazole110$1,324
Pantoprazole Sodium115$1,282
Sucralfate34$1,213
Famotidine104$988
Ondansetron OdtOndansetron12$64
Furosemide14$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$98$47,37714 claims
AbbVieLinzess$608$19,55622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,955 physician assistant providers in Indiana.

Other physician assistant in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →